01 Expansion of Next-Generation Sequencing and Minimally Invasive Testing Molecular diagnostics is moving from single-target laboratory tests toward broader panels, next-generation sequencing, and minimally invasive sampling. These tools can examine several genes or pathogens at once, helping clinicians select treatments, detect drug resistance, and reach answers faster. Liquid biopsy and circulating DNA analysis are also extending molecular testing beyond tissue samples, particularly in cancer care and treatment monitoring. At the same time, automated platforms and digital interpretation software are reducing manual work and making complex results easier to use. This shift is increasing the importance of high-quality genomic databases, validated analysis tools, and tests that deliver clinically useful information rather than large amounts of raw data. January 2026: The US FDA issued guidance supporting the use of molecular minimal residual disease measurements as clinical trial endpoints in multiple myeloma drug development.
01 Growing Need for Rapid and Accurate Disease Detection The growing need for faster and more accurate detection of infectious diseases, cancer, and inherited disorders is increasing demand for molecular diagnostics. PCR and sequencing-based tests identify genetic material directly, allowing clinicians to confirm disease, distinguish strains, and detect treatment-related biomarkers. This can shorten the time between symptoms, diagnosis, and therapy while reducing dependence on slower culture or less-specific methods. Public health programmes are also expanding molecular testing to identify drug resistance and control disease transmission. As precision medicines increasingly require confirmation of a particular mutation or biomarker, hospitals and laboratories need validated companion tests that connect diagnostic results with appropriate treatment decisions.
01 High Costs and Uneven Reimbursement Limit Routine Testing High testing costs and uneven reimbursement can limit the routine use of advanced molecular diagnostics. Sequencing instruments, specialised reagents, software, quality controls, and trained laboratory staff require considerable investment. A test may also identify many genetic changes without proving that every result improves patient care. Insurers and public health systems therefore often demand strong clinical-utility evidence before providing coverage. When payment is unavailable or differs by region, hospitals may restrict testing to selected patients, while laboratories face uncertain sample volumes and revenue. These barriers are particularly serious for rare diseases and broad genomic panels, where evidence collection is difficult and per-patient analysis can remain expensive.
01 Near-Patient Molecular Testing Expands Diagnostic Access Near-patient molecular testing creates an opportunity to extend accurate diagnosis beyond central laboratories. Compact PCR and sequencing systems can support clinics, community health centres, and regional hospitals where sample transport causes delays. Faster local results can help clinicians begin treatment earlier, isolate infectious patients, and identify antimicrobial resistance before ineffective medicines are prescribed. The opportunity is especially strong in countries expanding tuberculosis, respiratory disease, and outbreak surveillance programmes. Developers that provide simple workflows, stable reagents, affordable cartridges, and remote quality support can reach underserved locations. Connecting these systems with digital reporting platforms can also improve disease surveillance while creating recurring demand for consumables, software, and maintenance services.
01 Quality Control and Regulatory Differences Complicate Commercialization Maintaining consistent accuracy across laboratories and complex genetic targets remains a central market challenge. Molecular results can be affected by sample quality, contamination, low target levels, genetic variation, and differences in software interpretation. False-positive or false-negative findings may lead to unnecessary treatment or missed disease, making validation and external quality assessment essential. Laboratories must also protect sensitive genomic information while transferring results between instruments, hospitals, and digital databases. Regulatory requirements can differ across countries and change as laboratory-developed tests become more complex. These factors increase development time and documentation costs, while uncertainty over oversight can delay investment and make international product launches harder to coordinate.
June 2026 Agilent Technologies completed the acquisition of Biocare Medical, expanding its clinical pathology and molecular diagnostics portfolio with complementary antibodies, reagents, and diagnostic technologies to strengthen oncology and precision diagnostics offerings.
May 2026 Roche entered into a definitive merger agreement to acquire PathAI, integrating AI-powered digital pathology capabilities with its molecular diagnostics portfolio to accelerate biomarker discovery, companion diagnostics, and laboratory workflow automation.
April 2026 QuidelOrtho completed the acquisition of LEX Diagnostics, adding the ultra-fast LEX VELO PCR platform to strengthen its point-of-care molecular diagnostics business and expand rapid infectious disease testing capabilities.
July 2025 Thermo Fisher Scientific launched the Applied Biosystems SeqStudio™ Flex Dx Genetic Analyzer, an IVD-capable capillary electrophoresis platform designed to support molecular diagnostic laboratories with enhanced genetic testing and clinical workflow efficiency.